Core Insights - Myriad Genetics announced the publication of the analytical validation of the FirstGene Multiple Prenatal Screen, demonstrating exceptional sensitivity and specificity for each test component [1][2] Group 1: Test Validation and Performance - The study assessed nearly 500 samples and found that every component of the FirstGene screen achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity [2] - The FirstGene screen is designed to analyze key aspects of maternal and fetal genomes simultaneously, enhancing accuracy and reproducibility [3] Group 2: Clinical Application and Utility - The FirstGene screen aims to streamline prenatal genetic risk assessment by combining aneuploidy screening, recessive screening, and fetomaternal antigen testing into a single assay [4] - The screen is currently being utilized in the CONNECTOR study, which evaluates its performance in real-world clinical practice and aims to support clinical validity and utility [5] Group 3: Technological Innovation - The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to improve genotype resolution [3] - The publication of these results is considered a significant milestone towards the broad commercialization of the FirstGene screen [3]

Group 1 - ArrowMark Financial Corp. announced the preliminary results of its transferable rights offering, which commenced on January 22, 2026, and expired on February 18, 2026, allowing rights holders to subscribe for up to 2,604,156 shares of common stock at a subscription price of $19.79 per share [1][2] - The gross proceeds from the offering are expected to be approximately $37,000,000, which the Fund intends to invest in accordance with its investment objectives and policies [2] Group 2 - ArrowMark Financial Corp. is a non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol "BANX," with an investment objective to provide shareholders with current income by primarily investing in regulatory capital securities of financial institutions [4]

Core Insights - Maris-Tech Ltd. has received its first substantial production order for its Jupiter Drone edge video processing systems from a major player in the defense loitering munitions sector, marking a transition from pilot projects to operational supply [1][2] - The order signifies the customer's shift from evaluation to operational deployment, indicating the maturity and integration readiness of Maris-Tech's technology [2] Company Overview - Maris-Tech specializes in AI-powered edge video solutions for defense and security operations, focusing on real-time situational awareness and intelligence gathering in environments with bandwidth and latency constraints [4] - The Jupiter architecture supports advanced onboard video encoding, AI-driven analytics, and mission-critical processing, enabling autonomous targeting and real-time decision support [3][4] Market Position - The CEO of Maris-Tech stated that this order represents a significant milestone for the company, reinforcing its position as a technology provider for next-generation loitering defense systems [4] - Maris-Tech's platforms are utilized across various military applications, including UAVs, UGVs, and armored vehicles, demonstrating their capability in ultra-low-latency video processing and onboard AI analytics [4]

Core Viewpoint - C3is Inc. reported strong financial results for Q4 and the full year 2025, with significant increases in net income and EBITDA, driven by operational efficiency and fleet expansion strategies [14]. Operational and Financial Highlights Fourth Quarter 2025 Results - The company achieved revenues of $10.6 million in Q4 2025, up from $9.4 million in Q4 2024, with a daily Time Charter Equivalent (TCE) rate increase of 24% to $19,469 [4][9]. - Fleet operational utilization improved to 93.5% in Q4 2025 from 90.2% in Q4 2024, attributed to fewer idle days [4][9]. - Net income for Q4 2025 was $5.2 million, with an EBITDA of $6.7 million and earnings per share (EPS) of $5.82, compared to a loss of $51.51 per share in Q4 2024 [4][9][14]. - The company maintained a cash balance of $14.9 million as of December 31, 2025, despite significant capital expenditures [4][14]. Twelve Months 2025 Results - Total voyage revenues for 2025 were $34.8 million, down from $42.3 million in 2024, primarily due to increased idle days and drydocking of the Aframax tanker [9][10]. - Net income for the year was $10.5 million, a 481% increase from 2024, with EBITDA rising 244% to $17 million [14]. - The average number of vessels owned increased to 4.0 in 2025 from 3.6 in 2024, contributing to operational efficiency [11][14]. - The company reported a significant decrease in interest and finance costs from $2.5 million in 2024 to $0.4 million in 2025, reflecting the repayment of previous loans [13][14]. Fleet and Market Position - C3is Inc. operates a fleet of four vessels, including three Handysize dry bulk carriers and one Aframax tanker, with a total capacity of 213,464 deadweight tons (dwt) [18]. - The company has agreements to acquire two additional product tankers, which will expand fleet capacity by 387% from inception [16][18]. - The operational strategy focuses on capitalizing on strong market fundamentals, including elevated freight rates and resilient oil demand, with expectations for continued growth in global seaborne trade [15][16].

Core Insights - The 2026 Cloud and AI Security Risk Report by Tenable reveals a significant AI exposure gap, with organizations inheriting cyber risks faster than they can manage them [1][2] Group 1: Key Findings - 86% of organizations have installed third-party code packages with critical-severity vulnerabilities, making the software supply chain a major source of cloud exposure [7] - 65% of organizations possess "ghost" secrets, which are unused or unrotated cloud credentials, with 17% of these linked to critical administrative privileges [7] - 70% of organizations have integrated at least one AI or Model Context Protocol (MCP) third-party package, often without central security oversight [7] Group 2: Security Risks - Non-human identities, such as AI agents and service accounts, represent a higher risk (52%) compared to human users (37%), leading to dangerous combinations of permissions [7] - Organizations face severe risks in four key areas: AI security posture, supply chain attack vectors, least privilege implementation, and cloud workload exposure [2][4] - The lack of visibility and governance in AI systems embedded in infrastructure poses critical risks that need to be addressed [4] Group 3: Recommendations - Organizations should secure the AI integration process through comprehensive visibility and identity-centric controls, including enforcing least privilege for AI roles [4] - Steps to reduce extended supply chain exposure include unifying visibility across code packages, virtual machines, identity access, and cloud environments [4] - The report provides actionable guidance for security and business leaders to mitigate risks in cloud and AI environments [2]

SHELTON, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) will release its financial results for Fourth Quarter 2025 on Thursday, February 26, 2026, at 6:30 AM Eastern Time. A conference call to discuss these results will be broadcast over the internet on Thursday, February 26, 2026, at 12:00 p.m. Eastern Time. To listen to or participate in a question-and-answer session, dial 1-877-407-0784; international callers dial 1-201-689-8560, conference ID: 13758729. Access to t ...

Core Insights - Air Canada and Pegasus Airlines have formed a new partnership to enhance travel options to Türkiye, specifically to Istanbul and Izmir [1][3][5] Group 1: Partnership Details - The interline agreement allows Air Canada customers to book travel on nine routes operated by Pegasus Airlines, facilitating connections through major European gateways [5][7] - The partnership aims to deepen collaboration with future codeshare and loyalty agreements, enhancing customer benefits [3][6][7] Group 2: Strategic Importance - This partnership strengthens Air Canada's connectivity to a growing market, providing customers with increased choice and flexibility in travel [5][6] - The collaboration is expected to enhance travel convenience with features like single itineraries and through-checked baggage [7] Group 3: Company Profiles - Air Canada is the largest airline in Canada, serving over 180 airports globally and is a founding member of Star Alliance [8] - Pegasus Airlines, established in 1990, operates as a low-cost carrier with a network of 158 destinations across 55 countries, focusing on budget-friendly travel [9]

Group 1 - MISTRAS Group, Inc. has scheduled a conference call for March 5, 2026, at 9:00 am Eastern Time to present its fourth quarter results for 2025 [1] - A press release with the fourth quarter results will be issued after the market closes on March 4, 2026 [1] - Individuals can pre-register for the live question and answer session at a specified link [2] Group 2 - MISTRAS Group, Inc. is a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, serving critical industries such as oil & gas, aerospace & defense, power & utilities, manufacturing, and civil infrastructure [3] - The company offers a diversified portfolio of products and services, including advanced non-destructive testing, pipeline inspections, real-time condition monitoring, maintenance planning, and specialized engineering [3] - MISTRAS Group utilizes a proprietary management software suite that centralizes integrity data for predictive analytics and benchmark analysis, helping clients reduce risk, extend asset life, and optimize operational performance [3]

Company Overview - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, particularly asthma and COPD [3] - The company is headquartered in San Diego, California and is advancing rademikibart, a next-generation antibody targeting IL-4Rα [3] Product Development - Connect Biopharma is conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, which are areas with significant unmet medical needs [3] - The company has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million upon achieving certain development, regulatory, and commercial milestones [3] - Connect is also eligible to receive tiered royalties on net sales in Greater China, with rates up to low double-digit percentages [3] Upcoming Events - Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET [1] - A live webcast of the presentation will be available on the company's investor website, with an archived replay accessible for approximately 90 days following the conference [2]

Propelled by its leadership in Social Intelligence and Agentic AI, Sprout Social ranks as a top company across 6 categories based on customer reviewsCHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sprout Social (Nasdaq: SPT), an industry-leading provider of social media management and analytics software, has been recognized by G2’s 2026 Best Software Awards. This milestone marks the tenth consecutive year Sprout has received this honor, which ranks the world’s most impactful software companies and products based ...